RT Journal Article
SR Electronic
T1 Effectiveness and Safety of Anti-IL-5/Rα Biologics in Eosinophilic Granulomatosis with Polyangiitis: A Two-Year Multicenter Observational Study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4753
DO 10.1183/13993003.congress-2023.PA4753
VO 62
IS suppl 67
A1 Nolasco, Santi
A1 Portacci, Andrea
A1 Campisi, Raffaele
A1 Buonamico, Enrico
A1 Pelaia, Corrado
A1 Benfante, Alida
A1 Triggiani, Massimo
A1 Spadaro, Giuseppe
A1 Caiaffa, Maria Filomena
A1 Scioscia, Giulia
A1 Detoraki, Aikaterini
A1 Valenti, Giuseppe
A1 Papia, Francesco
A1 Tomasello, Alessandra
A1 Crimi, Nunzio
A1 Scichilone, Nicola
A1 Pelaia, Girolamo
A1 Carpagnano, Giovanna Elisiana
A1 Crimi, Claudia
YR 2023
UL http://erj.ersjournals.com/content/62/suppl_67/PA4753.abstract
AB Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, blood and tissue eosinophilia.Aim: To assess the effectiveness and safety of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in patients with EGPA for 24 months.Material and Methods: We conducted a multicenter observational study, including 49 patients (31 females, 63.3%) with EGPA treated with anti-IL-5/Rα biologics at 9 Italian outpatients’ facilities. Remission rates [Birmingham Vasculitis Activity Score (BVAS) =0 and prednisone (or equivalent) of ≤4.0 mg/day], corticosteroids (OCS) intake and respiratory outcomes were assessed.Results: Overall, BVAS score dropped from 6 (4-10) to 0 (0-0) (p<0.0001) at 24 months; 57.1% achieved remission after 24 months. The median OCS dose was reduced from 10 mg/day (5-20) to 2.5 mg/day (0.0-5) (p<0.0001) at 24 months; 69.6% of OCS-dependent patients lowered their daily dose by 75% and 28.3% discontinued these drugs. Multivariate analysis found that lower OCS intake [OR 0.8 (95% CI 0.67-0.93), p=0.0040] and higher blood eosinophil count [OR 1.002 (95% CI 1.0-1.003), p=0.0180] at baseline were independently associated with remission at 24 months. Asthma exacerbation dropped from 4 (3-5.8) to 0 (0-0.5) at 24 months (p<0.0001). The ACT score increased from 13.5 (10-17) to 22 (20-24) (p<0.0001) after 24 months. The pre-bronchodilator FEV1% improved from 77% (59.3-89.5) to 81.5% (71.5-100.5) (p<0.0001) at 24 months.Conclusions: These real-world data suggest that anti-IL-5/Rα biologics are effective and safe in the management of EGPA.FootnotesCite this article as: European Respiratory Journal 2023; 62: Suppl. 67, PA4753.This abstract was presented at the 2023 ERS International Congress, in session “Inflammatory endotyping: the macrophage across disease areas”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).